Px Wire

Px Wire is AVAC's quarterly update on biomedical HIV prevention research. Each issue includes a comprehensive time line of ongoing efficacy trials around the world and a map showing where these trials are happening. Each issue also includes updates on news, emerging issues and upcoming events.

January-March, Volume 5, Number 1
To start off the issue, we identify 10 key outcomes to pursue in order to make progress in beginning to end the AIDS epidemic. This issue also covers:

• Gilead Science’s submission to FDA for a label change for TDF/FTC (brand name Truvada) indicating that it can be used as HIV prevention in HIV-negative adults.
• The closure of the 1% tenofovir gel arm of the VOICE trial, which is evaluating oral and topical tenofovir-based PrEP—and a review of other key trials of tenofovir gel.
• New trials launched this quarter including the French IPERGAY pilot for an efficacy trial of coitally-related oral PrEP using TDF/FTC in MSM.
• The first meeting of Project ARM (Africa for Rectal Microbicides)—a new civil society initiative focused on rectal microbicides research and anal health.

The latest issue is available as a PDF and as a webpage.


Download graphics from the latest issue of Px Wire:

- Map of Ongoing HIV Prevention Research Trials (PDF, JPG, PPT)
- Timeline of HIV Prevention Efficacy and Follow-on Trial Results (PDF, JPG, PPT)




     

---

Px Wire Archive: View Px Wire issues starting from January 2008

---